LOS ANGELES, May 17 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Tuesday granted emergency use authorization (EUA) for a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children 5 through 11 years of age at least five months after completion of the primary vaccine series.
On Jan. 3, the FDA authorized the use of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine for individuals 12 through 15 years of age after completion of primary vaccination.
Join our Telegram channel to get our Evening Alerts and breaking news highlights
